NASDAQ: IKT - Inhibikase Therapeutics, Inc.

Yield per half year: +152.07%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Inhibikase Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc.

more details
has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2020-12-23
ISIN US45719W1062
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.inhibikase.com
Цена ао 2.29
Change price per day: -0.3268% (3.06)
Change price per week: -4.69% (3.2)
Change price per month: +11.72% (2.73)
Change price per 3 month: +160.68% (1.17)
Change price per half year: +152.07% (1.21)
Change price per year: +140.16% (1.27)
Change price per 3 year: +87.12% (1.63)
Change price per 5 year: 0% (3.05)
Change price per 10 year: 0% (3.05)
Change price per year to date: +48.78% (2.05)
All parameters

Underestimation

Title Value Grade
P/S 25.18 1
P/BV 0.5975 10
P/E 0 0
EV/EBITDA 0.0996 10
Total: 5.13

Efficiency

Title Value Grade
ROA, % -131.17 0
ROE, % -173.34 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0312 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % -76.32 0
Yield Ebitda, % 249.34 10
Yield EPS, % 3.72 1
Total: 6.2
More

Institutions Volume Share, %
Armistice Capital, LLC 186046 3.01
Vanguard Group Inc 87447 1.42
Blair (William) & Company, L.L.C. 59375 0.96
Geode Capital Management, LLC 28692 0.46
Redmond Asset Management, LLC 20977 0.34
Edgewood Management Llc 16666 0.27
Renaissance Technologies, LLC 16122 0.26
State Street Corporation 10084 0.16
Tower Research Capital LLC (TRC) 2200 0.04
Morgan Stanley 1667 0.03



Head Job title Payment Year of birth
Dr. Milton H. Werner Ph.D. CEO, President & Director 697.96k 1964 (61 year)
Dr. Surendra Singh Head of Chemistry, Manufacturing & Controls N/A
Dr. Charles Warren Olanow B.Sc., F.R.C.P.C., M.D. CEO of Clintrex Research Corporation & Member of Scientific Advisory Board N/A
Dan Williams Controller N/A
Mr. Garth Lees-Rolfe CPA Chief Financial Officer N/A 1985 (40 years)

Address: United States, Atlanta. GA, 3350 Riverwood Parkway SE - open in Google maps, open in Yandex maps
Website: https://www.inhibikase.com